Heidelberg Pharma · ISIN: DE000A11QVV0

EQS-News: Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma

EQS-News: Heidelberg Pharma AG / Key word(s): Study Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma 13.01.2025 / 08:17 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma Progress...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

This news feed is a compilation of company-relevant news from the most popular and widest-reaching newswire services. The feed is updated several times. For market-related publications, we recommend the X-Billboard, the Daily News Digest or our Premium Information Service.
Most recent update: 13.01.2025 | 08:17
13 January 2025 08:17AM
EQS-News: Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma
EQS-News: Heidelberg Pharma AG / Key word(s): Study Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma 13.01.2025 / 08:17 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma Progress...
© EQS Newswire
06 November 2024 10:02AM
EQS-News: Heidelberg Pharma: Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024
EQS-News: Heidelberg Pharma AG / Key word(s): Conference Heidelberg Pharma: Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024 06.11.2024 / 10:02 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma: Promisin...
© EQS Newswire
24 October 2024 11:03AM
EQS-News: Heidelberg Pharma to Participate in Leading Scientific and Financial Conferences in November 2024
EQS-News: Heidelberg Pharma AG / Key word(s): Conference Heidelberg Pharma to Participate in Leading Scientific and Financial Conferences in November 2024 24.10.2024 / 11:03 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma to Participate in Leading Scien...
© EQS Newswire
10 October 2024 07:06AM
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2024
EQS-News: Heidelberg Pharma AG / Key word(s): 9 Month figures Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2024 10.10.2024 / 07:06 CET/CEST The issuer is solely responsible for the content of this announcement. Heidelberg Pharma AG: Interim Management Statement on the First Nine Mont...
© EQS Newswire
01 October 2024 05:29PM
EQS-News: Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient
EQS-News: Heidelberg Pharma AG / Key word(s): Study results Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient 01.10.2024 / 17:29 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelb...
© EQS Newswire
01 October 2024 03:27PM
EQS-Adhoc: Heidelberg Pharma AG Announces Updated Guidance
EQS-Ad-hoc: Heidelberg Pharma AG / Key word(s): Forecast Heidelberg Pharma AG Announces Updated Guidance 01-Oct-2024 / 15:27 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this...
© EQS Newswire
23 September 2024 01:05PM
EQS-News: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024
EQS-News: Heidelberg Pharma AG / Key word(s): Conference Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024 23.09.2024 / 13:05 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE H...
© EQS Newswire
23 September 2024 01:05PM
EQS-News: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024
EQS-News: Heidelberg Pharma AG / Key word(s): Conference Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024 23.09.2024 / 13:05 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE H...
© EQS Newswire
11 July 2024 07:05AM
EQS-News: Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business
EQS-News: Heidelberg Pharma AG / Key word(s): Half Year Report Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business 11.07.2024 / 07:05 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma Reports on First Half-Year 2024 and the Course...
© EQS Newswire
21 June 2024 11:16AM
EQS-News: Heidelberg Pharma reports on the results of the Annual General Meeting 2024
EQS-News: Heidelberg Pharma AG / Key word(s): AGM/EGM Heidelberg Pharma reports on the results of the Annual General Meeting 2024 21.06.2024 / 11:16 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma reports on the results of the Annual General Meeting 202...
© EQS Newswire
18 June 2024 01:47PM
EQS-Adhoc: Heidelberg Pharma AG announces updated guidance
EQS-Ad-hoc: Heidelberg Pharma AG / Key word(s): Change in Forecast Heidelberg Pharma AG announces updated guidance 18-Jun-2024 / 13:47 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the conten...
© EQS Newswire
23 May 2024 09:12AM
EQS-News: Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
EQS-News: Heidelberg Pharma AG / Key word(s): Conference Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024 23.05.2024 / 09:12 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma to Participate and P...
© EQS Newswire
23 May 2024 09:12AM
EQS-News: Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
EQS-News: Heidelberg Pharma AG / Key word(s): Conference Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024 23.05.2024 / 09:12 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma to Participate and P...
© EQS Newswire
25 April 2024 07:21AM
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024
EQS-News: Heidelberg Pharma AG / Key word(s): Quarterly / Interim Statement Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024 25.04.2024 / 07:21 CET/CEST The issuer is solely responsible for the content of this announcement. Heidelberg Pharma AG: Interim Management Statement on the...
© EQS Newswire
05 April 2024 09:30AM
EQS-News: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
EQS-News: Heidelberg Pharma AG / Key word(s): Miscellaneous Heidelberg Pharma to host R&D Webinar following novel data presented at AACR 05.04.2024 / 09:30 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma to host R&D Webinar following novel data...
© EQS Newswire
05 April 2024 09:30AM
EQS-News: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
EQS-News: Heidelberg Pharma AG / Key word(s): Miscellaneous Heidelberg Pharma to host R&D Webinar following novel data presented at AACR 05.04.2024 / 09:30 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma to host R&D Webinar following novel data...
© EQS Newswire
27 March 2024 09:01AM
EQS-News: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
EQS-News: Heidelberg Pharma AG / Key word(s): Miscellaneous Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101 27.03.2024 / 09:01 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma granted orphan drug desig...
© EQS Newswire
25 March 2024 07:10AM
EQS-News: Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
EQS-News: Heidelberg Pharma AG / Key word(s): Annual Results Heidelberg Pharma announces financial figures and reports on successful business performance in 2023 25.03.2024 / 07:10 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma announces financial figu...
© EQS Newswire
19 March 2024 09:47AM
EQS-News: Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty
EQS-News: Heidelberg Pharma AG / Key word(s): Financing Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty 19.03.2024 / 09:47 CET/CEST The issuer is solely responsible for the content of this announcemen...
© EQS Newswire
18 March 2024 07:25AM
EQS-News: Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study
EQS-News: Heidelberg Pharma AG / Key word(s): Study Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study 18.03.2024 / 07:25 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma a...
© EQS Newswire
06 March 2024 07:46AM
EQS-News: Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
EQS-News: Heidelberg Pharma AG / Key word(s): Conference Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024 06.03.2024 / 07:46 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharm...
© EQS Newswire
04 March 2024 11:19AM
EQS-News: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
EQS-News: Heidelberg Pharma AG / Key word(s): Financing Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million 04.03.2024 / 11:19 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma Announces Royalty Finan...
© EQS Newswire
04 March 2024 11:02AM
EQS-Adhoc: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
EQS-Ad-hoc: Heidelberg Pharma AG / Key word(s): Financing Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million 04-March-2024 / 11:02 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group...
© EQS Newswire

The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.

AI First: Feel free to test the AI integration that will quickly put you on a par with financial journalists and research houses

Further information

The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.

The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.

If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.